Bradley Chipps, MD
Allergy · Sacramento, CANPI 1073524740
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by AstraZeneca at 48.9% of the total. Reporting peaked in 2019 at $234,049 and has fallen 79.4% since, to $48,242 in 2025. Among allergy clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 865 payments — averaging $659.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$279K
- Sanofi$69K
- Regeneron Healthcare Solutions, Inc.$63K
- Boehringer Ingelheim$31K
- Genentech USA, Inc.$29K
- F. Hoffmann-la Roche AG$27K
- plus $72K from 42 others
Across 46 payments — averaging $4006.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$117K
- F. Hoffmann-la Roche AG$35K
- Astrazeneca UK Limited$24K
- Novartis$4K
- Sanofi-aventis U.S. LLC$3K
- Sanofi$750
- plus $420 from 1 others
What the payments were for
- Consulting fees$295,64452%
- Speaking & faculty fees$212,90737%
- Grants$4,5001%
- Travel & lodging$37,5607%
- Food & beverage$20,0564%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$141,619
- DUPIXENT$95,106
- XOLAIR$58,224
- AIRSUPRA$49,575
- SPIRIVA$24,338
- TEZSPIRE$14,073
- NUCALA$6,500
- TRELEGY ELLIPTA$5,200
- BREZTRI AEROSPHERE$5,100
- STIOLTO RESPIMAT$4,608
- BREZTRI$4,205
- CINQAIR$2,587
- QVAR$2,470
- PULMICORT RESPULES$2,000
- SPIRIVA RESPIMAT$1,979
- NO PRODUCT DISCUSSED$1,500
- BEYFORTUS$1,142
- CINRYZE$122
How this compares
$570,768 in reported general payments places this provider in the 95th percentile of 117 allergy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 182 | $678,215 |
| XolairOmalizumab | 139 | $391,587 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 212 | $191,075 |
| TezspireTezepelumab-Ekko | 36 | $145,910 |
| Spiriva RespimatTiotropium Bromide | 162 | $136,291 |
| Breo ElliptaFluticasone/Vilanterol | 207 | $133,445 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 157 | $126,798 |
| Dupixent PenDupilumab | 31 | $124,493 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $116,480 |
| FasenraBenralizumab | 17 | $93,307 |
| SymbicortBudesonide/Formoterol Fumarate | 228 | $90,044 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 24 | $87,755 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 19 | $75,120 |
| AlvescoCiclesonide | 74 | $54,043 |
| Zileuton ErZileuton | 14 | $52,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Fasenra, Symbicort, Airsupra | $279,045 | $491,934510 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $20,783 | $442,927578 claims |
| Genentech, Inc.Xolair | $91 | $391,587139 claims |
| CSL BehringPrivigen, Hizentra | $23 | $204,23537 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $31,464 | $164,239199 claims |
| Grifols USA, LLCGamunex-C | $91 | $75,12019 claims |
| Covis Pharma GmbHAlvesco | $140 | $54,04374 claims |
| MerckDulera | $3,888 | $37,77273 claims |
| Hikma Pharmaceuticals USAEpinephrine | $68 | $20,78676 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $5,230 | $18,36759 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $179 | $7,45713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 117 allergy providers in California.
Other allergy in Sacramento
- Stanley ChengSacramento$16K
- Joshua JacobsWalnut Creek$1.5M
- Warner CarrLaguna Niguel$571K
- Travis MillerRoseville$273K
- Robert ZeigerSan Diego$162K
- William BergerMission Viejo$76K
- Sandra ChristiansenSan Diego$74K
- Stephen WongHacienda Heights$50K
- Michelle YasharpourBeverly Hills$48K
- Stuart EpsteinBeverly Hills$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.